The Ritchie Centre, Monash Institute of Medical Research, Monash University, Clayton, Victoria;
J Neurosurg Spine. 2014 Jun;20(6):657-69. doi: 10.3171/2014.2.SPINE13760. Epub 2014 Apr 4.
Following microdiscectomy, discs generally fail to undergo spontaneous regeneration and patients may experience chronic low-back pain and recurrent disc prolapse. In published studies, formulations of mesenchymal progenitor cells combined with pentosan polysulfate (MPCs+PPS) have been shown to regenerate disc tissue in animal models, suggesting that this approach may provide a useful adjunct to microdiscectomy. The goal of this preclinical laboratory study was to determine if the transplantation of MPCs+PPS, embedded in a gelatin/fibrin scaffold (SCAF), and transplanted into a defect created by microdiscectomy, could promote disc regeneration.
A standardized microdiscectomy procedure was performed in 18 ovine lumbar discs. The subsequent disc defects were randomized to receive either no treatment (NIL), SCAF only, or the MPC+PPS formulation added to SCAF (MPCs+PPS+SCAF). Necropsies were undertaken 6 months postoperatively and the spines analyzed radiologically (radiography and MRI), biochemically, and histologically.
No adverse events occurred throughout the duration of the study. The MPC+PPS+SCAF group had significantly less reduction in disc height compared with SCAF-only and NIL groups (p < 0.05 and p < 0.01, respectively). Magnetic resonance imaging Pfirrmann scores in the MPC+PPS+SCAF group were significantly lower than those in the SCAF group (p = 0.0213). The chaotropic solvent extractability of proteoglycans from the nucleus pulposus of MPC+PPS+SCAF-treated discs was significantly higher than that from the SCAF-only discs (p = 0.0312), and using gel exclusion chromatography, extracts from MPC+PPS+SCAF-treated discs also contained a higher percentage of proteoglycan aggregates than the extracts from both other groups. Analysis of the histological sections showed that 66% (p > 0.05) of the MPC+PPS+SCAF-treated discs exhibited less degeneration than the NIL or SCAF discs.
These findings demonstrate the capacity of MPCs in combination with PPS, when embedded in a gelatin sponge and sealed with fibrin glue in a microdiscectomy defect, to restore disc height, disc morphology, and nucleus pulposus proteoglycan content.
在接受微创手术切除椎间盘后,椎间盘通常无法自发再生,患者可能会经历慢性腰痛和椎间盘再次突出。在已发表的研究中,间充质祖细胞与戊聚糖多硫酸酯(MPCs+PPS)的制剂已被证明可在动物模型中再生椎间盘组织,表明该方法可能是微创手术切除的有用辅助手段。本临床前实验室研究的目的是确定将 MPCs+PPS 嵌入明胶/纤维蛋白支架(SCAF)中,并移植到微创手术切除造成的椎间盘缺损中是否可以促进椎间盘再生。
在 18 个绵羊腰椎间盘进行标准化微创手术切除。随后的椎间盘缺损随机接受以下治疗:不治疗(NIL)、仅 SCAF 或 SCAF 中添加 MPC+PPS 制剂(MPCs+PPS+SCAF)。术后 6 个月进行尸检,对脊柱进行放射学(X 线摄影和 MRI)、生物化学和组织学分析。
整个研究过程中均未发生不良事件。与仅 SCAF 组和 NIL 组相比,MPCs+PPS+SCAF 组的椎间盘高度降低明显较少(p < 0.05 和 p < 0.01)。MPCs+PPS+SCAF 组的磁共振成像 Pfirrmann 评分明显低于 SCAF 组(p = 0.0213)。从 MPC+PPS+SCAF 治疗的椎间盘的髓核中提取的蛋白聚糖的变性溶剂萃取率明显高于仅 SCAF 组(p = 0.0312),并且使用凝胶排阻色谱法,从 MPC+PPS+SCAF 治疗的椎间盘的提取物也含有比其他两组更高百分比的蛋白聚糖聚集物。对组织学切片的分析表明,与 NIL 或 SCAF 组相比,66%(p > 0.05)的 MPC+PPS+SCAF 治疗的椎间盘退变程度较轻。
这些发现表明,当 MPC 与 PPS 一起嵌入明胶海绵中并用纤维蛋白胶密封在微创手术切除的椎间盘缺损中时,具有恢复椎间盘高度、椎间盘形态和髓核蛋白聚糖含量的能力。